Yonsei Med J.  2017 Jan;58(1):144-149. 10.3349/ymj.2017.58.1.144.

Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis

Affiliations
  • 1Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. geniushee@yuhs.ac

Abstract

PURPOSE
Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC).
MATERIALS AND METHODS
The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response.
RESULTS
Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024).
CONCLUSION
BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.

Keyword

Beclomethasone dipropionate; ulcerative colitis; clinical remission; clinical response

MeSH Terms

Administration, Oral
Anti-Inflammatory Agents/*administration & dosage/adverse effects
Beclomethasone/*administration & dosage/adverse effects
Colitis, Ulcerative/drug therapy
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Male
Medical Records
Remission Induction
Republic of Korea
Retrospective Studies
Safety
Treatment Outcome
Young Adult
Anti-Inflammatory Agents
Beclomethasone

Figure

  • Fig. 1 Oral beclomethasone dipropionate efficacies after 4 weeks of treatment.

  • Fig. 2 Oral beclomethasone dipropionate treatment outcomes according to disease activity.


Cited by  1 articles

Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea
Ji Young Chang, Sung-Ae Jung, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Ki-Nam Shim
Intest Res. 2018;16(4):599-608.    doi: 10.5217/ir.2018.00012.


Reference

1. Lee HJ, Jung ES, Lee JH, Hong SP, Kim TI, Kim WH, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology. 2012; 59:1415–1420.
2. Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol. 2014; 20:11525–11537.
Article
3. Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, et al. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012; 59:118–140.
Article
4. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010; 4:1–14.
Article
5. Saibeni S, Meucci G, Papi C, Manes G, Fascì-Spurio F. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame? Expert Rev Gastroenterol Hepatol. 2014; 8:949–962.
Article
6. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J. 1975; 51:Suppl 4. 20–25.
7. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010; 4:28–62.
Article
8. Levine DS, Raisys VA, Ainardi V. Coating of oral beclomethasone dipropionate capsules with cellulose acetate phthalate enhances delivery of topically active antiinflammatory drug to the terminal ileum. Gastroenterology. 1987; 92:1037–1044.
Article
9. Fascì Spurio F, Aratari A, Margagnoni G, Doddato MT, Chiesara F, Papi C. Oral beclomethasone dipropionate: a critical review of its use in the management of ulcerative colitis and Crohn's disease. Curr Clin Pharmacol. 2012; 7:131–136.
Article
10. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14:1660–1666.
Article
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317:1625–1629.
Article
12. Choi JH, Kim ES, Cho KB, Park KS, Lee YJ, Lee SM, et al. Old age at diagnosis is associated with favorable outcomes in Korean patients with inflammatory bowel disease. Intest Res. 2015; 13:60–67.
Article
13. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19:Suppl A. 5A–36A.
Article
14. Yamada S, Yoshino T, Matsuura M, Kimura M, Koshikawa Y, Minami N, et al. Efficacy and safety of long-term thiopurine maintenance treatment in Japanese patients with ulcerative colitis. Intest Res. 2015; 13:250–258.
Article
15. Jeon SR, Kim WH. Is long-term therapy with thiopurines effective for maintaining remission in patients with moderate-to-severe ulcerative colitis? Intest Res. 2015; 13:191–192.
Article
16. Campieri M, Adamo S, Valpiani D, D'Arienzo A, D'Albasio G, Pitzalis M, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 2003; 17:1471–1480.
Article
17. Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2002; 16:1109–1116.
Article
18. Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, et al. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci. 2010; 55:2002–2007.
Article
19. Nunes T, Barreiro-de Acosta M, Nos P, Marin-Jiménez I, Bermejo F, Ceballos D, et al. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. J Crohns Colitis. 2010; 4:629–636.
Article
20. Van Assche G, Manguso F, Zibellini M, Cabriada Nuño JL, Goldis A, Tkachenko E, et al. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. Am J Gastroenterol. 2015; 110:708–715.
Article
21. Kim DH, Park SJ, Park JJ, Yun YH, Hong SP, Kim TI, et al. Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. Dig Dis Sci. 2014; 59:2514–2522.
Article
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr